Supernus, Inc.

Indivior is the market leader in long-acting injectable medications for opioid use disorder, developing and delivering evidence-based pharmacotherapies that support long-term patient recovery. The company generates revenue primarily through two product lines: SUBLOCADE, a monthly long-acting buprenorphine injection that serves as its flagship offering, and sublingual formulations including SUBOXONE Film and Tablets. Indivior sells its products through direct customers such as wholesalers and specialty pharmacies as well as indirect customers including government-sponsored programs and commercial insurers, generating revenue net of substantial deductions for government rebates, commercial rebates, product returns, and other allowances.